Pre-Grant Publication Number: 20100311694
View Prior Art submitted by the community. You can see full text, rate and annotate the Prior Art by clicking on
any of the listed Prior Art references. You can also click on the name of the person who submitted art to view their profile
and any other Prior Art they have previously submitted.
How to Rate Prior Art
Rating Prior Art - Click the thumbs up or down to indicate if a submission is relevant enough to the claims of the application to deserve a spot in the Top 10 submissions that will be forwarded to the patent examiner. Rating should be based only on relevance. For an explanation of prior art, please visit the Tutorial Page.
Rating Prior Art - Click the thumbs up or down to indicate if a submission is relevant enough to the claims of the application to deserve a spot in the Top 10 submissions that will be forwarded to the patent examiner. Rating should be based only on relevance. For an explanation of prior art, please visit the Tutorial Page.
Prior Art (4)
Title Clinical Cancer Research
ISBN
Description
This journal article published prior to the patent's Chinese filing date describes using 17-Nucleoside derivatives of geldanamycin in human pancreatic cancer cells. Significant anti-tumor effects were noted.
Title Organic & Biomolecular Chemistry
Description
Journal article published online just before the patent's filing date. Appears to potentially be relevant to claims, but I can't access the full article.
Title erbB-2 Oncogene Inhibition by Geldanamycin Derivatives: Synthesis, Mechanism of Action, and Structur
Description
Journal Medical Chemistry describes some compounds that were also claimed in this patent.
Patent/Application # wo2003013430
Description
he invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.
0 days left
